Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants - Wikidata - wikimedia - TriplyDB

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

http://www.wikidata.org/entity/Q35605724

about

Contributions of human enzymes in carcinogen metabolism Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility.High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.Interindividual differences in phytochemical metabolism and disposition Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility.Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention.Differences in metabolite-mediated toxicity of tamoxifen in rodents versus humans elucidated with DNA/microsome electro-optical arrays and nanoreactors.Interindividual differences in response to plant-based diets: implications for cancer risk.Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.Glucuronidation of tobacco-specific nitrosamines by UGT2B10 Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Transcriptional regulation of human UDP-glucuronosyltransferase genes.UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.Screening of multiple hormonal activities in surface water and sediment from the Pearl River system, South China, using effect-directed in vitro bioassays.Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

P2860

Q30520640-59AB1BBF-3B8F-4278-8B5D-5F2190FE9504 Q33714571-49DBF180-0BC3-4F64-A305-896F5326DA2B Q33714575-8B0B60EA-F0A9-4A93-82B4-1512340FFA15 Q34044936-3152CF5D-3DE9-454D-B1BD-A354F38B558E Q34125047-AAC1ACC3-E350-4876-8CF4-65E746265BAA Q34307873-BE5D63A7-22D6-417A-9B77-D16FBA086F8D Q34774040-4AC45EFF-84D1-40EE-9AEF-36E070ECDEBB Q35008045-1406D008-5398-4FCD-8F14-2C4B0FC20D0A Q35691825-78F505D9-3D0A-4CB5-AF8E-6C34A702F809 Q36132293-8F45581B-57F0-4452-B9F6-C0713E0E2561 Q36148997-DBBC064A-013F-4610-B3EE-54E6A27BC7AC Q36406279-74CF7138-BAE6-4F1B-9990-9F9A64645B2B Q37000698-F8DE4E6B-AE2D-4A70-96A5-EB67C2BC9800 Q37133759-60A372D3-A1A5-4DA4-9277-C04780B9B9AB Q37179160-2F6F1DA1-6D0A-466D-8E46-1CF3C77F36B5 Q37195375-A6FF38A2-D5B8-44A0-A092-971FE9C08B19 Q37221922-628C2118-DF29-4F0B-B0EB-38B94478270E Q37271209-444FE2BA-7422-42BB-9CD7-DD7A504C15F3 Q37271799-06DD7017-D03A-424A-8903-690DA9B5181A Q37663398-75DC79D5-12C4-408D-9C38-555F6BBFF72C Q38030052-6E4AACBC-D656-444D-B510-7176F6A4101F Q38103593-041C573B-5F78-419A-A635-DB7559D96DE5 Q38105253-F1F12AF2-440B-4D96-A8B4-ADEE91CB4763 Q38261875-81A37299-6298-46E8-8BC9-1EEF9F33B096 Q39647877-A3CC9BB1-EFD9-4BB8-9DDE-C3CDF23D3A3D Q39868674-7BA2C743-C84A-466A-A8EF-566CFE6DBDE8 Q40789462-66A3DD0F-CCB9-4182-9FD9-50F2AC90064C Q45153204-A7C32E45-E2FD-41AD-9F27-7252A69EDE29 Q48334328-EE626DD3-5E4E-4F09-8F36-6FE87107D100 Q52613905-9BDB3FC3-BE2F-4744-A678-CE1648396A58 Q57072034-D18DF07D-7408-4545-AFC2-A88690BD5810

P2860

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

http://www.wikidata.org/entity/Q35605724

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@ast

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@en

type

label

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@ast

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@en

prefLabel

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@ast

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@en

P1433

Q35605724-75DD5F82-D9A1-4B62-BB73-4FC30F4F1519

P1476

Q35605724-3E038299-5BDD-40A1-BE37-0FE7C916F7D8

P2093

Q35605724-096C153D-B78C-465F-86B6-AE440241E77A

Q35605724-10BFB591-FAB0-4201-81AA-59948A539244

Q35605724-593077C2-32F4-4B11-B923-F0A3A075EFBC

Q35605724-8E156E0C-D97D-4160-8EF8-1A242386F83F

Q35605724-B1312203-B5E5-46AB-B238-8CE7C085D299

Q35605724-D517536F-6AEB-4A2B-9698-931429719DD3

P2860

Q35605724-050CF2E1-E44B-412C-A97E-7CB3E2EA55EC

Q35605724-09707655-FD9A-48AA-A806-56D146A70B2F

Q35605724-0FA56C97-9F93-4F6B-BCAE-F5A9BC9DBA36

Q35605724-20A928F9-85A6-4140-8101-428BDC4B9D8D

Q35605724-23E7AD12-CDA1-479D-A395-139F1A45FABB

Q35605724-244F2CFC-5D78-41E5-842F-47877A2331E9

Q35605724-274793B5-C6FD-4737-87CB-4C4B2148B898

Q35605724-2A37F62C-E118-46E4-8CAA-AE47ED7F7109

Q35605724-2E06FF2B-A19F-42B0-9011-B0507B660E6C

Q35605724-3336512C-654F-4FE0-BD47-CD7A11D78931

P2888

Q35605724-8B7B6FDB-B987-4389-A8F8-37EC79C4ED27

P304

Q35605724-5302F781-E48E-4076-9BFD-8DB8128CF404

P31

Q35605724-A3B9C563-35F3-4126-95EB-12573EB7A919

P356

Q35605724-A9E6AAEC-CF11-4768-85C3-AD4E69021154

P433

Q35605724-2BDBEB82-9E33-44C4-A489-C4E52C2A30B3

P478

Q35605724-A740316A-2620-43A2-9376-20C5339B47AC

P577

Q35605724-F1627DD9-E073-4128-8E42-C926BECFF6D2

P5875

Q35605724-4C06D22C-B337-4BBF-A816-4C8E175919F2

P6179

Q35605724-55D7D1D5-BDEE-4A37-B543-0D97D0BE5713

P698

Q35605724-802949D9-4B50-4519-B2E9-F077DEB12B0D

P932

Q35605724-58E1768D-49DE-4EC3-B640-99C87B03D729

P356

P1433

Breast Cancer Research

P1476

Characterization of tamoxifen ...... ation by human UGT1A4 variants

@en

P2093

Dongxiao Sun

http://www.w3.org/2001/XMLSchema#string

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Jia-Long Fang

http://www.w3.org/2001/XMLSchema#string

Kimberly Duncan

http://www.w3.org/2001/XMLSchema#string

Philip Lazarus

http://www.w3.org/2001/XMLSchema#string

Ryan W Dellinger

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4

The pharmacology and clinical uses of tamoxifen

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Tamoxifen and risk of idiopathic venous thromboembolism

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Overview of the main outcomes in breast-cancer prevention trials.

New approaches to the endocrine prevention and treatment of breast cancer.

P2888

P304

R50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1539

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6901371

http://www.w3.org/2001/XMLSchema#string

P6179

1022284965

http://www.w3.org/2001/XMLSchema#string

P698

16884532

http://www.w3.org/2001/XMLSchema#string

P932

1779459

http://www.w3.org/2001/XMLSchema#string